Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 11:21 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 3049–3072 of 145,503 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Disorders Clear all

Conditions: Ulcerative Colitis
Interventions: LY4268989, Mirikizumab, LY4268989 Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 40
States / cities: Scottsdale, Arizona • Anaheim, California • Lancaster, California + 36 more

Conditions: Non-alcoholic Fatty Liver Disease
Interventions: Magnetic Resonance Imaging (MRI); Procedure
Lead sponsor: Emory University; Other
Eligibility: 7 Years to 18 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Angelman Syndrome
Interventions: GTX-102; Drug
Lead sponsor: Ultragenyx Pharmaceutical Inc; Industry
Eligibility: 4 Years to 17 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 6
States / cities: Los Angeles, California • San Diego, California • Atlanta, Georgia + 3 more

Conditions: Multiple Myeloma
Interventions: Lenalidomide, Dexamethasone, Elranatamab; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Dry Eye Syndromes, Neuropathic Pain
Interventions: Naloxone Hydrochloride 0.4 MG/ML; Drug
Lead sponsor: Seema Capoor; Other
Eligibility: 18 Years to 65 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Vitiligo
Interventions: RECELL® Autologous Cell Harvesting Device; Device
Lead sponsor: Avita Medical; Industry
Eligibility: 18 Years and older
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 17
States / cities: Scottsdale, Arizona • Irvine, California • San Diego, California + 13 more

Conditions: Chronic Pain, Musculoskeletal Pain
Interventions: Treatment as usual (TAU), Brief Cognitive Behavioral Therapy for Chronic Pain (Brief CBT-CP); Other · Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 79 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Bullous Pemphigoid
Interventions: efgartigimod PH20 SC, Prednisone; Biological · Drug
Lead sponsor: argenx; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 6
States / cities: Phoenix, Arizona • Fountain Valley, California • Miami, Florida + 3 more

Conditions: Sickle Cell Disease, Executive Dysfunction, Cognitive Impairment, Attention Deficit/Hyperactivity Disorder (ADHD)
Interventions: Extended-Release Methylphenidate; Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 8 Years to 17 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Non-small Cell Lung Cancer (NSCLC), Lung Cancer, Neoplasm Metastasis
Interventions: Bevacizumab, Pemetrexed, Vitamin B12, Folate, Dexamethasone; Drug
Lead sponsor: Heather Wakelee; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2016
U.S. locations: 4
States / cities: Stanford, California • Lebanon, New Hampshire • Voorhees Township, New Jersey + 1 more

Conditions: Recurrent or Metastatic PD-L1-positive Squamous Cell Carcinoma of the Head and Neck
Interventions: MEDI4736; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 38
States / cities: Birmingham, Alabama • Yuma, Arizona • Duarte, California + 32 more

Conditions: Advanced Cancer, Hypogonadism, Pain
Interventions: Questionnaire, Blood draws to assess gonadal function; Behavioral · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Malignant Solid Tumour, Hematologic Malignancies, Planned Hematopoietic Cell Transplantation
Interventions: Physical performance testing and patient-generated health data; Other
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Major Depressive Disorder
Interventions: Buprenorphine, Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Stanford, California

Conditions: Brain Neoplasm, Neoplasm Metastasis
Interventions: Cytovene (Ganciclovir Sodium), G1TKSVNa.53 Producer Cell Line; Drug · Device
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 19 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1992 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Whiplash Injury of Cervical Spine, Muscle Weakness
Interventions: Not listed
Lead sponsor: D'Youville College; Other
Eligibility: 19 Years to 70 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Tallahassee, Florida • Tampa, Florida

Conditions: Lymphocyte-Rich Classical Hodgkin Lymphoma, Recurrent Lymphocyte-Depleted Classical Hodgkin Lymphoma, Recurrent Mixed Cellularity Classical Hodgkin Lymphoma, Recurrent Nodular Sclerosis Classical Hodgkin Lymphoma, Refractory Lymphocyte-Depleted Classical Hodgkin Lymphoma, Refractory Mixed Cellularity Classical Hodgkin Lymphoma, Refractory Nodular Sclerosis Classical Hodgkin Lymphoma
Interventions: Carboplatin, Etoposide, Ifosfamide, Laboratory Biomarker Analysis, Pembrolizumab; Drug · Other · Biological
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 6
States / cities: Atlanta, Georgia • Augusta, Georgia • Chicago, Illinois + 3 more

Conditions: Gallbladder Cancer, Liver Cancer, Bile Duct Cancer
Interventions: questionnaires; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Major Depressive Disorder
Interventions: Resistance Exercise Training; Behavioral
Lead sponsor: Iowa State University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Ames, Iowa

Conditions: Multiple Myeloma
Interventions: hTERT vaccine, GM-CSF, PCV, T cell infusion, GM-CSF, PCV, T cell infusion; Biological
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 80 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2017
U.S. locations: 2
States / cities: Baltimore, Maryland • Philadelphia, Pennsylvania

Conditions: Type 2 Diabetes
Interventions: Continuous Glucose Monitor, Patient Reported Outcome Questionnaires; Device · Other
Lead sponsor: Stanford University; Other
Eligibility: 4 Years to 19 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Stroke, Traumatic Brain Injury, Non-traumatic Brain Injury
Interventions: Philips GoLite Blu HF3429/60, Philips LivingColor Aura 70998/60/48; Other
Lead sponsor: St. Luke's Rehabilitation Institute; Other
Eligibility: 18 Years to 85 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Spokane, Washington

Conditions: Major Depressive Disorder (MDD), Major Depressive Disorder With Anxious Distress
Interventions: SPT-300; Drug
Lead sponsor: Seaport Therapeutics; Industry
Eligibility: 18 Years to 66 Years
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 22
States / cities: Chino, California • Garden Grove, California • Glendale, California + 19 more

Conditions: Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis
Interventions: HealthPROMISE users, Control Group; Other
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:

Validation of HepaFat-Scan for Noninvasive Measurement of Steatosis in Youth

A Study of the Safety and Tolerability of GTX-102 in Children With Angelman Syndrome

ERd Combination Treatment in Newly Diagnosed Multiple Myeloma (ADVANCE 2.0)

Topical Naloxone to Diagnose Ocular Pain

Repigmentation of Stable Vitiligo Lesions Using Spray-On Skin™ Cells

Brief Cognitive Behavioral Therapy for Chronic Pain

A Phase 3 Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid

Methylphenidate to Address Attention and Executive Deficits Among Children With Sickle Cell Disease

Phase 2 Trial of Bevacizumab in Combination With Pemetrexed

Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Prevalence of Secondary Hypogonadism in Male Patients on Chronic Opioid Therapy for Cancer-Related Pain Syndromes

Assessing Physical Fitness in Cancer Patients With Cardiopulmonary Exercise Testing and Wearable Data Generation

Opiate Suicide Study in Patients With Major Depression

Gene Therapy for the Treatment of Brain Tumors

Influence of Directional Preference on Movement Coordination Deficits in Individuals With Whiplash Associated Disorders

Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Quality Of Life in Patients With Malignant Biliary Obstruction

Feasibility of Resistance Exercise to Treat Major Depression Via Cerebrovascular Mechanisms

Phase I/II Clinical Trial Combining hTERT Tumor Vaccine & Autologous T Cells in Patients With Advanced Myeloma

Use of Continuous Glucose Monitors in Publicly-Insured Youth With Type 2 Diabetes - A Pilot and Feasibility Study

Daily Light Exposure for Sleep Disturbance, Fatigue, and Functional Outcomes in Acute Brain Injury

An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study)

Trial on Impact of HealthPROMISE Mobile App on Inflammatory Bowel Disease Care and Quality of Life